Researchers: Three Common Antiviral Medications Possibly Efficacious Against COVID

Researchers: Three Common Antiviral Medications Possibly Efficacious Against COVID
Published on

A team of researchers has found that three commonly used antiviral and antimalarial drugs are effective in vitro at preventing replication of SARS-CoV-2, the virus that causes Covid-19.

The study, published in the journal ACS Omega, looked at three antiviral drugs that have proven effective against Ebola and the Marburg virus — tilorone, quinacrine, and pyronaridine.

Follow NewsGram on Twitter to stay updated about the World news.

"We were looking for compounds that could block the entry of the virus into the cell," said researcher Anna Puhl from the University of North Carolina in the US.

The research examined three antiviral drugs that have been shown to be effective against Ebola and the Marburg virus. Pixabay

"We chose these compounds because we know that other antivirals which successfully act against Ebola are also effective inhibitors of SARS-CoV-2," Puhl added.

For the study, the compounds were tested in vitro against SARS-CoV-2, as well as against a common cold virus (HCV 229E) and murine hepatitis virus (MHV).

The researchers utilized a variety of cell lines that represented potential targets for SARS-CoV-2 infection in the human body. They infected the cell lines with the different viruses and then looked at how well the compounds prevented viral replication in the cells.

The team found that the results were mixed, with the compounds' effectiveness depending upon whether they were used in human-derived cell lines versus monkey-derived cell lines, known as Vero cell lines.

"In the human-derived cell lines, we found that all three compounds worked similarly to remdesivir, which is currently being used to treat Covid-19," the researchers said.

The next steps for the research include testing the compounds' effectiveness in a mouse model and further work on understanding how they inhibit viral replication. (IANS/KB)

logo
NewsGram
www.newsgram.com